EFPIA Annual Report 2015 From Innovation To

2y ago
5 Views
2 Downloads
2.38 MB
13 Pages
Last View : 22d ago
Last Download : 2m ago
Upload by : Dani Mulvey
Transcription

EFPIA Annual Report 2015@EFPIAIntroductionForewordAbout EFPIAImpact ofmedicines in EuropeMedicines costsin contextEFPIAActivity 2015InnovationOutcomes driven,sustainable healthcareDatawww.efpia.euEFPIA Annual Report 2015From innovation to outcomesEFPIA memberCompanies / AssociationsEFPIABoard Members1

EFPIA Annual Report 2015@EFPIAIntroductionForewordAbout EFPIAImpact ofmedicines in EuropeMedicines costsin contextEFPIAActivity 2015InnovationOutcomes driven,sustainable healthcareDataEFPIA memberCompanies / AssociationsEFPIABoard Memberswww.efpia.euThe industry is committed to working with allstakeholders in healthcare to underscore theimportance of relationships and to ensure that thebenefits of greater transparency are understoodIntroductionto Annual Report 2015Dialogue and partnership have never been so important.As European healthcare systems continue to grapple with risingdemand, driven by an ageing population and the increased prevalenceof chronic disease, I have witnessed a growing recognition that nosingle part of the healthcare eco-system in isolation can provideall the solutions. To address these significant challenges requiresnew approaches to and higher levels of dialogue, partnershipand collaboration. EFPIA and its member companies have beencommitted to and engaged in these processes throughout 2015.Our commitment is no better illustrated than by the InnovativeMedicines Initiative (IMI), Europe’s successful partnership forhealth. Tackling issues such as anti-microbial resistance, better useof healthcare data and the evolution of the European regulatoryenvironment – in line with advances in science and a range oftherapy areas – IMI continues to bring together academia, healthcaresystems, regulators and industry, to tackle some of the mostsignificant challenges in speeding the path of innovative medicinesto patients.RICHARDBERGSTRÖMDirector General,EFPIA2015 witnessed the celebration of the 50th Anniversary ofpharmaceutical legislation in Europe, which has made a significantcontribution to science, medicine and patients. As its membercompanies forge ahead with creating an exciting, new waveof pharmaceutical innovation, EFPIA continues to work withstakeholders to ensure that the regulatory and policy environmentkeeps pace with the rapidly-advancing science, supporting projectsthat include the EMA-led ADAPT SMART, and programmes thatfoster access to life-changing treatments for the right patientgroups, at the earliest appropriate time in the product life-span, in asustainable fashion.New innovation is only meaningful, though, if patients across allEuropean Member States are able to access it. During 2015, EFPIAand its member companies have been working with governmentsand healthcare systems to find solutions to improve access tomedicines and the sustainability of healthcare, at the same timesecuring future medical innovation. We have witnessed the adventof new approaches, such as outcomes-based reimbursement andmanaged entry agreements, as well as the development of nationalstability pacts that balance budget stability and access to medicines,with support for new innovation.In additional to the comprehensive coverage of EFPIA’s activitiesthroughout the year, the 2015 Annual report focuses on a range of keyissues across European healthcare, scrutinising and appraising theimpact of medicines, the role of data in the future of healthcare andthe adoption of outcomes-based, sustainable models of healthcaredelivery. As I look forward to 2016, continuing the dialogue, developingpartnerships and effective collaboration will be key to meeting themany challenges faced by healthcare in Europe. EFPIA and itsmember companies are committed to playing their part.Yours faithfully,New partnerships in 2015, extended to the creation of the EuropeanMedicines Verification Organisation, a landmark step in the fightagainst counterfeit medicines. Set up on 13 February 2015, EMVOis a not-for-profit stakeholder organisation that represents a keytool in combatting the emergence of falsified medicines in the EUlegitimate supply chain and improving patient safety. It represents theculmination of four years of intensive work towards a dependable andsecure pharmaceutical verification system.Meaningful partnerships mean finding new, open and transparentways of working together. During 2015, EFPIA members companieshave been collecting data on collaborations with health professionalsand healthcare organisations, which will be disclosed publicly in June2016. It will be the first time ever that these transfers of value havebeen made public across Europe, and the industry is committedto working with all stakeholders in healthcare to underscore theimportance of these relationships and to ensure that the benefits ofgreater transparency are understood.Richard Bergström 2

EFPIA Annual Report 2015@EFPIAIntroductionForewordAbout EFPIAImpact ofmedicines in EuropeMedicines costsin contextEFPIAActivity 2015InnovationOutcomes driven,sustainable healthcareDataEFPIA memberCompanies / AssociationsEFPIABoard Members www.efpia.euDuring 2015, EFPIA and its member companies have been workingwith governments and healthcare systems to find solutions to improveaccess to medicines and the sustainability of healthcare, at thesame time securing future medical innovationForeword by the President2015 was an important year for the European pharmaceutical industry. It marked the 50year anniversary of the EU Pharmaceutical Legislation, 20 years since the foundation of theEuropean Medicines Agency, and 15 years since the EU Orphan Medicines Regulation cameinto effect.Looking back, what has been achieved is impressive. We now havemedicines for many conditions we were unable to treat before.EMA has approved a total of 975 medicines1 since its foundation,many of which first in class. 140 therapies alone have received amarketing authorisation for diseases so rare they affect no more than5 in 10,000 Europeans2. Medicines are also safer than ever before.We have a rigorous regulatory framework and a world-class medicinesagency in Europe. High standards for clinical trials ensure strict safetystandards for products coming to market. Robust pharmacovigilancesystems are used to monitor the safety of products in clinical practice.Today’s medicines are also more effective than ever before. HIVcan now be treated like a chronic condition, with death rates down75% since 20043. We can cure Hepatitis C with a 12 week course ofmedicine. New therapies for Rheumatoid Arthritis target the causes ofinflammation rather than treating the symptoms alone.JOE JIMENEZEFPIA PresidentCEO Novartis1234This tremendous progress is the result of continued researchinvestments of our companies, combined with an effectiveintellectual property and regulatory framework. In the EU alone, weinvested on average 25 billion Euros every year in the last decade4.These investments have also laid the foundation for additionalbreakthroughs in the next years. Cell therapy may allow the reprogramming of a patient’s own T-cells so that they attack the cancercells in the patient’s body. This would be a true step-change in thefight against cancer. The promise of gene therapy is to replace adefective gene that causes a disease with a healthy copy of that geneand ultimately help us cure diseases like Cystic Fibrosis. Advances indisease-modifying therapy could also provide genuine solutions forAlzheimer’s disease.European Medicines Agency opinions on human and veterinary medicines, http://www.ema.europa.eu/docs/en GB/document library/Other/2015/01/WC500180920.pdf.European Medicines Agency, 1995-2015 – Celebrating 20 years, http://www.ema.europa.eu/docs/en GB/document library/Brochure/2015/03/WC500184383.pdf.HIV/AIDS surveillance in Europe 2013, WHO Regional Office for Europe & European Centre for Disease Prevention and Control (ECDC), November 2014 cited in EFPIA, the pharmaceutical industry in figures (2015).EU Industrial R&D Investment Scoreboards 2005-2015, r, our industry must help healthcare systems in Europebecome sustainable as they face a rapidly ageing population. In orderfor Europe to deal with demographic change ahead, and to ensuresustainable access to innovation, the industry and the systems weoperate in must continue to evolve. Building on our work in 2015, Isee three areas of focus going forward:In 2015, we have initiated several projects to accelerate the transitiontowards an outcomes-based approach to healthcare. Systematicallytracking health interventions and their impact on outcomesallows systems to allocate resources where they deliver the bestpossible outcomes. Eliminating interventions that don’t work freesup the needed resources to address the healthcare needs of anageing population. In 2016, the IMI “Big Data 4 Better Outcomes”programme will see the formation of public-private consortia. Thesewill agree common outcomes definitions, build the data needed tomeasure outcomes, and identify options to improve outcomes in keydisease areas. Our “Value of Health” initiative that seeks to buildpolitical will to move towards an outcomes-focused approach will alsocontinue into 2016. With “Healthier Futures” we will launch EFPIA’svision for an outcomes-driven sustainable future.Sustainable access was another priority in 2015. We engagedwith healthcare decision makers across Europe to explore if a panEuropean system for Relative Efficacy Assessments (REA) couldbe established. These clinical assessments of new medicines arecurrently done separately in each Member State, based on nationalmethodologies. This not only creates access delays for patients; italso leads to unequal access across Europe, which we aim to solvein collaboration with Member States. While REA should be donescientifically at the European level, pricing and reimbursementmust be kept at the country level, due to the different culturesand values that determine what a country is willing to pay for aninnovation. We will also build on our work with EMA to co-developsystems for adaptive approval and access, so that innovationreaches patients as early as possible without compromising safety.Through the Innovative Medicines Initiative, we will continue tocoordinate collaborative responses to global health threats likeantimicrobial resistance.2015 also showed that healthcare systems were unprepared forsome of the innovations coming to market. Going forward, weneed to help our healthcare system partners understand betterwhat type of innovations are coming and their impact onhealthcare systems. With enough time to plan ahead, systems canmake relevant adjustments to allow new therapies to deliver theirfull potential. The way forward may be novel financing models,structural changes, or new capabilities. Partnering with healthcaresystems in a solution-oriented way will enable us to jointly realisethe promise of new medicines, while ensuring the right incentivesare in place for future innovation.I look forward to continuing to work with our stakeholders on thisjourney.Joe Jimenez3

EFPIA Annual Report 2015@EFPIAIntroductionForewordAbout EFPIAImpact ofmedicines in EuropeMedicines costsin contextEFPIAActivity 2015InnovationOutcomes driven,sustainable healthcareDataEFPIA memberCompanies / AssociationsEFPIABoard Memberswww.efpia.euWe want systems that providepatients with equal and earlyaccess to the best and safestmedicines that empowerscitizens to make informeddecisions about their healthand ensure the highestsecurity of the medicinessupply chain.About EFPIAThe European Federation of Pharmaceutical Industries and Associations (EFPIA) representsthe pharmaceutical industry operating in Europe. Through its direct membership of 33 nationalassociations and 42 leading pharmaceutical companies, EFPIA is the voice in Brussels of 1,900companies committed to researching, developing and bringing to patients new medicines thatwill improve health and the quality of life around the world.Our VisionWe support a vision of outcomes-driven, sustainable healthcare systems in Europe. We wantsystems that provide patients with equal and early access to the best and safest medicines;that support innovation while balancing realistically benefit and risk; that empowers citizens tomake informed decisions about their health and ensure the highest security of the medicinessupply chain. Such a vision will also assist policymakers in sustaining Europe’s economicgrowth and competitiveness, by balancing healthcare budgets and helping to provide for ahealthy and productive workforce. It also offers the most effective approach to deliver theinnovative medicines needed to tackle current and potential health threats.Our CommitmentImproving patient outcomes, developing sustainable models of healthcare, reducinginequalities in health, accelerating patients’ access to innovative medicines and improvingpatient safety – these are our primary commitments. By working in partnership with allhealthcare stakeholders, we seek to develop practical solutions to make these goals a reality.We believe that these commitments are in the best interest of Europe’s citizens. We willengage with all partners in healthcare delivery to discuss, design and implement policies thathelp us achieve these goals, while improving public health and economic wealth, as well asenhancing Europe’s industrial and science base.67 4

EFPIA Annual Report 2015@EFPIAIntroductionForewordAbout EFPIAImpact ofmedicines in EuropeMedicines costsin contextEFPIAActivity 2015InnovationOutcomes driven,sustainable healthcareDataEFPIA memberCompanies / AssociationsEFPIABoard Members www.efpia.euImpact of medicines in EuropeMedicines and vaccines are some of the most powerful tools that helppeople all over Europe to live longer, healthier and more productive lives.Over recent years, there has been dramatic, tangible progress in tacklingmajor diseases. There are numerous examples.MEDICINES ARE SOME OF THE MOST POWERFUL TOOLS IN TREATING AND CURING DISEASES95%of the 15 million patients in Europe livingwith HEPATITIS C Can be cured through an8-12 week course of treatment.94%Since 1991 there has been a 94% reductionin age-standardised death rates for patientsliving with HIV in France.37%Between 2000 and 2012, the death ratefrom CARDIOVASCULAR DISEASE fell37% in the EU5.31%21%Between 2000 and 2012, new therapiescontributed to a 48% and 31% decline inthe DIABETES death rate in Korea andCanada, respectively.Previously, the only hope for hepatitis C patients was livertransplantation. Those lucky to receive a donor organ had endurelife-long use of imunosuppressants. New hope has been given tothe 15 million people in Europe living with hepatitis C and, thanks topharmaceutical innovation, 95% of patients can be cured through a12-week course of medicine.New medicines are also helping to put healthcare systems on a moresustainable path by reducing costs in other parts of the system, suchas hospitalisations. New medicines have transformed the outlookfor patients living with cardio-vascular disease; death rates havefallen by 37% in the EU5 between 2000 and 2012 thanks, in part, tonew treatments that have revolutionised the way we manage highcholesterol. Per capita, expenditure on cardiovascular hospitalisationswould have been 70% higher in 2003, had new cardiovascular medicinesnot been introduced in the period 1995–2003. Ongoing innovation isexpected to reduce the future need for hospitalisation further.The value and impact of medicines goes beyond the individual andhealthcare systems to benefit wider society in Europe. Critical toEurope’s life science eco-system, the biopharmaceutical industryinvests more of its revenue in generating new knowledge throughresearch and development than any other sector and is the secondlargest funder of R&D in Europe. The pharmaceutical industrycontinues to generate essential economic value, with a Europeantrade surplus of 75 billion in 2013, employing around 700,000people, investing over 30 billion in European R&D and developingmedicines that improve patient productivity.MEDICINE USE YIELDS:SIGNIFICANT HEALTH GAINS AND SAVINGS IN OTHER PARTS OF HEALTHCARE SYSTEMSNew Cardiovascular MedicinesLed to Direct Savings onHospitalizations in 20 OECDCountries*, 1995-2004Cost of new medicines 24per capitaSince 1991 there has been a 21% reductionin mortality rates from all CANCERS.Source: Health Advances analysisCancer has touched the lives of many citizens in Europe. Formany patients and their families, new medicines have significantlyincreased chances of survival. Since their peak in 1991, death rateshave fallen by a 21% in the EU5. Today, 2 out of 3 people diagnosedwith cancer survive at least 5 years, with life expectancy for cancerpatients increasing by 1.74 years between 2000 and 2009, across 30OECD countries.Since the US Centre for Disease Control first used the term AcquiredImmune Deficiency Syndrome (AIDS) in September 1982, the worldwitnessed the catastrophic unfolding of the AIDS epidemic. Out ofthe tragedy, though, a story of innovation, collaborative research andultimately hope emerged. Beginning with the introduction of thefirst antiretroviral medicines in 1987, effective new treatments havetransformed HIV/AIDS from a death sentence to a manageable disease.Hospitalization–per 89capita*Countries included: EU5, Australia,Austria, Belgium, Canada, Czech Republic,Finland, Hungary, Japan, Korea, NewZealand, Norway, Poland, Slovak Republic,Spain, Switzerland, Turkey, USA.Per capita expenditure oncardiovascular hospitalizationswould have been 89 (70%)higher in 2003 had newcardiovascular medicines notbeen introduced in the period1995–2003.Source: Health Advances analysis5

EFPIA Annual Report 2015@EFPIAIntroductionForewordAbout EFPIAImpact ofmedicines in EuropeMedicines costsin contextEFPIAActivity 2015InnovationOutcomes driven,sustainable healthcareDataEFPIA memberCompanies / AssociationsEFPIABoard Members www.efpia.euTHE BIOPHARMACEUTICAL INDUSTRY MAKES A SIGNIFICANT CONTRIBUTION TO THEEUROPEAN ECONOMYEMPLOYMENT IN THE PHARMACEUTICALINDUSTRY 2013 75BILLIONMedicines costs in contextUK73,000GERMANY110,036 75 Billion was Europe’spharmaceutical tradesurplus in 2013During 2015, there has been intense debate around the affordability challengesfaced by healthcare systems, under pressure from rising healthcare demand.We recognise these concerns about the affordability of innovative medicines.FRANCE93,209SWITZERLAND40,913Spending on medicines should be considered in the context of theoutcomes they deliver and wider healthcare spending. The realityis that since 2009, spending on medicines in OECD countries hasactually fallen by an average of 1.8% per year. Of course, today’sinnovative medicines are tomorrow’s generics and bio-similars, andthat is why we have lower cost options for treating conditions suchas heart disease and depression today. This will extend to conditionslike cancer, rheumatoid arthritis, and other diseases in the future. Thisis the long-term, true value of innovation.There are many practical examples of this happening alreadythrough outcomes-based reimbursement contracts, managed entryagreements and other types of access and funding models fornew medicines. In the future, we believe we can build sustainablehealthcare systems by developing new pricing models, such asoutcomes-based, or value-based contracts. This is in its infancy andwill require partnering with patients, healthcare providers, payers andindustry to create a real breakthrough and overcome some of the initialchallenges, including gaps in legal systems, data, or capabilities.Although medicines account for less than one fifth of totalhealthcare spends in Europe, they are often the principle focus ofcost containment policies, rather than governments undertaking ananalysis of the entire healthcare spend, understanding total diseasecosts and identifying and reducing waste in the system.At national level, the industry, and an increasing number of Europeangovernments have created national stability agreements to ensureaffordable access to medicines. But much more effort is required toachieve system-wide solutions, especially in light of increasingly agedpopulations, which will put further strain on our healthcare systems.Our industry is committed to supporting the creation of outcomesbased healthcare systems that are fit for the challenges of the future.THE BIOPHARMACEUTICAL INDUSTRY INVESTS MORE OF ITS REVENUE IN GENERATINGNEW KNOWLEDGE THROUGH RESEARCH AND DEVELOPMENT THAN OTHER SECTORSWe would welcome taking an active role in this important transition,based on our commitment to the long-term sustainability ofhealthcare in Europe.R&D SPENDING AS APERCENTAGE OF NETSALES, 2014We share a common goal with all partners in healthcare: toensure that patients across Europe get rapid access to the latest,effective and life-saving medicines. That is why we are working withgovernments and healthcare systems to find solutions to makemedicines accessible and healthcare more sustainable.ITALY62,3001 in 6 are highly skilled R&D positionsSource: Pharmaceutical Industry in Figures, EFPIA 2015Average annual growth rates in real terms, %TOTAL HEALTHCARE EXPENDITURE HAS SEEN CONSTANT GROWTH WHILESPENDING ON MEDICINES HAS DECREASED BY 1.8% PER ANNUM IN RECENT 0.80.70-0.3-1-2-3-1.8Inpatient careSource: OECD Health at a Glance (2015)Outpatient careLong-term carePharmaceuticalsPreventionAdministrationSource: The 2015 EU industrial R&Dinvestment scoreboard, EuropeanCommission, JRC, DG RTD.14.4%10.1%8.0%4.5%4.4%2.6%Pharmaceuticals and biotechnologySoftware and computer servicesTechnology hardware and equipmentAerospace & defenceAutomobiles & partsChemicals6

EFPIA Annual Report 2015@EFPIAIntroductionForewordImpact ofmedicines in EuropeAbout EFPIAMedicines costsin contextEFPIAActivity 2015InnovationOutcomes driven,sustainable healthcareDataEFPIA memberCompanies / Associationswww.efpia.euEFPIABoard Members INDUSTRY IMPACTEFPIA published updated evidence on Health &Growth.TRADEEFPIA hosted a live Q&A on TTIP. The sessionreached over 350,000 Twitter accounts via 180participants.EFPIA Activity 2015ETHICSAt the invitation of the Biomed Alliance, EFPIAprovided industry comment as they developedtheir new code of ethics.TRANSPARENCYEFPIA member companies began collatingdata on transfers of value made tohealth professionals and healthcareorganisations. Transfers of value madein 2015, will be publicly disclosed bythe end of June 2016 - part of industry’swider commitment to transparency.TRADEEFPIA President Joseph Jimenez together withEFPIA Director General Richard Bergström, inpartnership with PhRMA, conducted a series ofhigh-level meetings with Chinese authoritiesand key stakeholders.FEB 15DEC 14ACCESS TO MEDICINESEFPIA and EuropaBio hosted an event on 15years after the Orphan Medicines Regulation,are rare disease patients getting the innovationand treatments they need? to review theopportunities made possible by the OMPregulation and underline challenges ahead.JAN 15FALSIFIED MEDICINESIn partnership with majorstakeholders, EFPIA announcesthe creation of the EuropeanMedicines VerificationOrganisation, a landmark stepin combating the emergenceof falsified medicines in the EUlegitimate supply chain.RESEARCH & DEVELOPMENTIllumina joins EFPIA as a memberof the Partners in Researchprogramme.GROWTHEFPIA launched the Access to financeand barriers to growth in the innovativebiopharmaceutical sector at the EuropeanBusiness Summit.APR 15MAR 15REGULATIONEFPIA hosted the 50 Year Anniversaryof EU Pharmaceuticals Legislation: Areexpectations for access to innovativemedicines and sciences being met today?examining the continuing role, challengesand opportunities for pharmaceuticallegislation in Europe.TRANSPARENCYEFPIA published guidance, aimed atensuring consistent and transparentreporting across the membership onthe European Commission – EuropeanParliament transparency register.TRADEEFPIA voiced the industry input in to TTIPthrough a meeting with the Chief negotiatorsduring the 10th round of negotiations andpublication of resources showcasing the benefitsof TTIP and separating the fact from fiction.JUN 15MAY 15NATIONAL STABILITY AGREEMENTSIn partnership with SIFFA, EFPIA signed anagreement with the government of Latvia that ledto the creation of a working group on new accessmodels for oncology products. Across Europe,governments and the biopharmaceutical industry aredeveloping stability agreements that balance accessto medicines with support for innovation. EFPIA issupporting these agreements in 5 countries of theCentral and Eastern European Region.HEALTH POLICYThe Universal Health Conference (Riga), organisedby EFPIA, EGA, EPHA and EPF, gathered stakeholdersfrom across the health community, culminating in anagreement on the Riga Roadmap – a concerted call foraction, asking EU institutions and national governmentsto apply specified measures in order to maximize healthand wellbeing and ensure the long-term sustainabilityof Europe’s health systems.EFPIA and AIPM organised a high-levelroundtable in Moscow, with the participation ofregulators and Ministers from the five countries(Russia, Belarus, Kazakhstan, Kyrgyzstan andArmenia) of the Eurasian Economic Union(EAEU). EU Member State regulators andDirector-General Richard Bergström shared theEU experience in creating a common regulatorysystem, and provided advice on the setup of acommon medicines market, ahead of the plannedentry into force of a regional EEU medicinesmarket on 1 January 2016.TRANSPARENCYEFPIA attended ECCO congress in Vienna,presenting on HCP-HCO disclosure and hostinga stand to answer delegates’ questions ontransparency.AUG 15JUL 15TRADEFinalized in August and officiallyconcluded in December 2015, EFPIAplayed an active role in the EU-VietnamFTA negotiations, a benchmark for futureFTA agreements in Asia.In partnership with member associations EFPIA inFrance, Italy, Portugal, Spain, Switzerland, Latvia,Slovakia and the UK, EFPIA rain a series of workshopson outcomes-based healthcare.HEALTH POLICYEFPIA responded to the Public Consultation on thepreliminary opinion on access to health services inthe European Union by the Expert Panel on effectiveways of investing in health, in November 2015.RESEARCH & DEVELOPMENTQuintiles and Somalogic joined EFPIA as Partners inResearch.TRANSPARENCYEFPIA launched the #pharmadisclosure social mediacampaign to raise awareness of the importance of therelationship between industry, health professionalsand healthcare organisations, as well as to provideinformation and resources on the public disclosure oftransfers of value to health professionals.OCT 15SEP 15DEC 15NOV 15JAN 16HEALTH TECHNOLOGY ASSESSMENTEFPIA and EUnetHTA co-hosted a meeting onRelative Efficacy Assessment, in particular theproduction of European joint assessments.NATIONAL STABILITY AGREEMENTSTo support stability, innovation and access tomedicines, supported by EFPIA, the industryin Bulgaria signed a Memorandum ofUnderstanding with the Minister of Health.TRADEAn EFPIA Delegation, led by vice-PresidentStefan Oschmann and Director-General RichardBergström, in partnership with EFPIA Japan, helda first exchange with Japanese officials and anevent for Japanese media.HEALTHCARE DATAGeneral Data Protection Regulationnegotiations were concluded with theinclusion of specific provisions to safeguardhealth research.HEALTH POLICYEFPIA supported and participated in a plenarysession entitled Health in all Policies at theEuropean Health Forum, Gastein.RESEARCH & DEVELOPMENTInterSystems joins EFPIA as a member of Partnersin Research.ACCESS TO MEDICINESEFPIA Director General, Richard Bergströmhosted the EFPIA DG Lecture, entitledInnovators or Speculators? Price, value andaccess to medicines in Europe. In the formatof a conversation between EFPIA DG RichardBergström and Menno Aarnout, ExecutiveDirector of the International Associationof Mutual Benefit Societies (AIM), theconversation focused on price, value andaccess to medicines in Europe.INNOVATIONEFPIA launched the Pipeline project tohighlight future pharmaceutical innovationand its impact on health outcomes, societiesand healthcare systems.EFPIA published the Putting animal welfare and the3Rs into practice report.In partnership with key European stakeholders,EFPIA was a partner in the launch of theMedsdisposal campaign to support best practice inthe safe disposal of medicines by consumers.13 OUTCOMES BASED HEALTHCAREEFPIA hosted the Health Collaboration Summit,bringing together over 200 senior figures from healthpolicy and patient organisations to discuss outcomesdriven, sustainable healthcare.EFPIA launches study on the economic footprintof the pharmaceutical industry in Europe.REGULATIONEFPIA is a key partner in the launch of theADAPT SMART consortium, an enablingplatform for the coordination of MedicinesAdaptive Pathways to Patients (MAPPs)activities. MAPPs seeks to foster access tobeneficial treatments for the right patient groupsat the earliest appropriate time in the productlife-span, in a sustainable fashion.7

EFPIA Annual Report 2015@EFPIAIntroductionForewordAbout EFPIAImpact ofmedicines in EuropeMedicines costsin contextEFPIAActivity 2015Innovation1www.efpia.euOutcomes driven,sustainable healthcareDataEFPIA memberCompanies / AssociationsEFPIABoard Members 2InnovationWith over 7000 medicines in development, this exciting, new wave ofmedical innovation will play a key role in addressing the challenges faced bypatients and healthcare systems.Innovation is the lifeblood of our industry, bringing with it hope forpatients in Europe and the wider world, while offering the prospectof long-term sustainability to health systems.This means new treatments for diseases such as cancer, diabetes,hepatitis C, cardio-vascular disease and neurological conditions, butalso encompasses a determined effort to ad

EFPIA Annual Report 2015 From innovation to outcomes @EFPIA www.efpia.eu EFPIA Annual Report 2015 Introduction Foreword About EFPIA 1 Impact of medicines in Europe Innovation EFPIA Activity 2015 Medicines costs in context

Related Documents:

EFPIA Key Data 2020 4 62.3% 10.4% Pharmerging comprises 21 6.5% 18.4 % Pharmerging Japan Europe (Top 5) Rest of the World USA 2.4% MAIN TRENDS The research-based pharmaceutical industry c

Summarize and document the risk assessment Identify additional control requirements, if required, to ensure PDE is met . www.efpia.eu 5 Industry Risk Assessment Example 1 Synthetic API – tablet . www.efpia.eu 6 Industry Risk Assessment Example 1 – Oral Solid Dose Product .

This document describes workflows for the quality risk management of nitrosamine risks in medicines, developed by experts from EFPIA's manufacturing and Quality Expert Group. The workflows and risk assessment principles described here are intended to support the accountabilities of medicine application holders and drug

2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 . Removal handle Sound output / wax protection system. 11 Virto V-10 Custom made shell Battery door Volume control (optional) Push button Removal handle . Before using

Alter Metal Recycling . 13 . 9/21/2015 156.73 9/24/2015 66.85 9/27/2015 22.24 9/30/2015 35.48 10/3/2015 31.36 10/6/2015 62.97 10/9/2015 36.17 10/12/2015 80.48 10/15/2015 84.99 10/18/2015 90.93 10/21/2015 82.

Phonak Bolero V70-P Phonak Bolero V70-SP Phonak Bolero V50-M Phonak Bolero V50-P Phonak Bolero V50-SP Phonak Bolero V30-M Phonak Bolero V30-P Phonak Bolero V30-SP CE mark applied 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 This user guide is valid for: 3 Your hearing aid details Model c

USD United States Dollar . Annual Report 2015 02 CHAIRMAN'S MESSAGE Dear friends and colleagues, I would like to take this opportunity to share with you the Annual Report of SHARP-Pakistan for the year 2015. Protecon has been the core focus area for SHARP since its incepon in 1998 and we are . Annual Report 2015.

Animal Food Fun & MORE. Instructions Equipment: Paper plate Thin card (not paper as it is too thin) Yellow and brown paint (or felt pen). Yellow bendy straws (you can colour paper ones) Sellotape Glue Elastic What to do: 1) Draw this shape on the back of your paper plate and cut it out carefully. (save this to make the ears). 2) Paint the front of both pieces of the .